MCID: ENC018
MIFTS: 58

Encephalopathy

Categories: Neuronal diseases, Rare diseases, Metabolic diseases, Eye diseases, Genetic diseases

Aliases & Classifications for Encephalopathy

MalaCards integrated aliases for Encephalopathy:

Name: Encephalopathy 50 50 28 51
Encephalopathies 69
Brain Diseases 69

Classifications:



External Ids:

ICD10 32 G93.4

Summaries for Encephalopathy

NINDS : 50 Aicardi-Goutieres syndrome (AGS) is an inherited encephalopathy that affects newborn infants and usually results in severe mental and physical handicap. There are two forms of the syndrome: an early-onset form that is severe, and a late-onset form that has less impact upon neurological function. The early-onset form affects about 20 percent of all babies who have AGS. These infants are born with neurological and liver abnormalities, such as enlargement of the liver and spleen and elevated liver enzymes. Their jittery behavior and poor feeding ability mimic congenital viral infection. Babies with later-onset AGS begin having symptoms after the first weeks or months of normal development, which appear as a progressive decline in head growth, weak or stiffened muscles (spasticity), and cognitive and developmental delays that range from moderate to severe. Symptoms last for several months, and include irritability, inconsolable crying, intermittent fever, seizures, and loss of developmental skills. Children may also have puffy swelling on the fingers, toes, and ears that resemble chilblains. A number of children have a noticeable startle reaction to sudden noise. For babies with the later-onset form, as symptoms lessen, there is no further worsening of the disease. AGS is difficult to diagnose since many of the symptoms are similar to those of other disorders. Diagnosis is made based on the clinical symptoms of the disease, as well as characteristic brain abnormalities that can be seen in an MRI brain scan. Cerebrospinal fluid (CSF), taken using a "spinal tap," can also be tested for increased levels of a specific immune system cell (a lymphocyte), which indicates a condition known as chronic lymphocytosis. These cells are normally only elevated during infection, so that lymphocytosis without evidence of infection can be used as an indicator of AGS. CSF may also be tested for elevated levels of a substance known as interferon-gamma, which can also support a diagnosis of AGS. The mutations of four different genes are associated with AGS: Aicardi-Goutieres syndrome-1 (AGS1) and AGS5 (an autosomal dominant form) are caused by a mutation in the TREX1 gene, AGS2 is caused by a mutation in the RNASEH2B gene, AGS3 is caused by a mutation in the RNASEH2C gene, AGS4 is caused by a mutation in the RNASEH2A gene. Most cases of AGS are inherited in an autosomal recessive manner, which means that both parents of a child with AGS must carry a single copy of the defective gene responsible for the disease. Parents do not have any symptoms of disease, but with every child they have together, there is a one in four chance that the baby will receive two copies of the defective gene and inherit AGS. NOTE: AGS is distinct from the similarly named Aicardi syndrome (characterized by absence of a brain structure (corpus callosum), and spinal, skeletal, and eye abnormalities).

MalaCards based summary : Encephalopathy, also known as encephalopathies, is related to epileptic encephalopathy, early infantile, 4 and infantile epileptic encephalopathy, and has symptoms including pseudobulbar signs, seizures and headache. An important gene associated with Encephalopathy is ETHE1 (ETHE1, Persulfide Dioxygenase), and among its related pathways/superpathways is Neuroscience. The drugs Ethanol and Heparin have been mentioned in the context of this disorder. Affiliated tissues include liver, brain and testes, and related phenotype is behavior/neurological.

Wikipedia : 72 Encephalopathy (/ɛnˌsɛfəˈlɒpəθi/; from Ancient Greek: ἐγκέφαλος \"brain\" + πάθος \"suffering\") means... more...

Related Diseases for Encephalopathy

Diseases in the Encephalopathy family:

Encephalopathy Due to Defective Mitochondrial and Peroxisomal Fission 1 Encephalopathy Due to Defective Mitochondrial and Peroxisomal Fission 2

Diseases related to Encephalopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 916)
# Related Disease Score Top Affiliating Genes
1 epileptic encephalopathy, early infantile, 4 33.5 SLC25A22 STXBP1
2 infantile epileptic encephalopathy 33.4 CDKL5 PCDH19 SCN1A STXBP1
3 early myoclonic encephalopathy 33.1 CDKL5 SCN1A SLC25A22
4 epileptic encephalopathy, early infantile, 9 33.1 CDKL5 MECP2 PCDH19 SCN1A
5 febrile infection-related epilepsy syndrome 32.6 PCDH19 SCN1A
6 epileptic encephalopathy, early infantile, 6 32.6 CDKL5 PCDH19 PNPO SCN1A SLC25A22 STXBP1
7 epileptic encephalopathy, early infantile, 15 32.6 CDKL5 GNAO1 PCDH19 PNPO SCN1A SLC25A22
8 west syndrome 32.0 CDKL5 MECP2 SCN1A SLC25A22 STXBP1
9 malignant migrating partial seizures of infancy 31.7 SCN1A SLC25A22
10 rett syndrome 29.3 CDKL5 MECP2 STXBP1
11 seizure disorder 28.8 CDKL5 MECP2 PNPO SCN1A
12 encephalopathy, ethylmalonic 12.3
13 wernicke encephalopathy 12.2
14 hypertensive encephalopathy 12.2
15 hepatic encephalopathy 12.2
16 encephalopathy, familial, with neuroserpin inclusion bodies 12.2
17 glycine encephalopathy 12.2
18 stxbp1 encephalopathy with epilepsy 12.2
19 3-methylglutaconic aciduria with deafness, encephalopathy, and leigh-like syndrome 12.2
20 encephalopathy, acute, infection-induced 4 12.2
21 chd2 myoclonic encephalopathy 12.1
22 mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes 12.1
23 mitochondrial neurogastrointestinal encephalopathy disease 12.1
24 epileptic encephalopathy, early infantile, 3 12.1
25 acute necrotizing encephalopathy type 1 12.1
26 scn8a-related epilepsy with encephalopathy 12.1
27 epileptic encephalopathy, early infantile, 7 12.1
28 acute necrotizing encephalopathy 12.1
29 glycine encephalopathy with normal serum glycine 12.1
30 epileptic encephalopathy, early infantile, 1 12.1
31 encephalopathy, progressive, with or without lipodystrophy 12.1
32 mecp2-related severe neonatal encephalopathy 12.0
33 encephalopathy, neonatal severe, due to mecp2 mutations 12.0
34 gnao1 encephalopathy 12.0
35 scn8a encephalopathy 12.0
36 encephalopathy due to defective mitochondrial and peroxisomal fission 1 12.0
37 epileptic encephalopathy, early infantile, 12 12.0
38 toxic encephalopathy 12.0
39 epileptic encephalopathy, early infantile, 26 12.0
40 epileptic encephalopathy, childhood-onset 12.0
41 epileptic encephalopathy, early infantile, 27 12.0
42 epileptic encephalopathy, early infantile, 25 12.0
43 hemorrhagic shock and encephalopathy syndrome 12.0
44 epileptic encephalopathy, early infantile, 29 12.0
45 epileptic encephalopathy, early infantile, 50 12.0
46 epileptic encephalopathy, early infantile, 35 11.9
47 epileptic encephalopathy, early infantile, 14 11.9
48 epileptic encephalopathy, early infantile, 28 11.9
49 epileptic encephalopathy, early infantile, 8 11.9
50 epileptic encephalopathy, early infantile, 2 11.9

Comorbidity relations with Encephalopathy via Phenotypic Disease Network (PDN): (show all 31)


3-Hydroxyacyl-Coa Dehydrogenase Deficiency Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Alzheimer Disease Bronchitis
Cerebral Atherosclerosis Cerebral Degeneration
Cerebrovascular Disease Chronic Kidney Failure
Chronic Myocardial Ischemia Decubitus Ulcer
Deficiency Anemia Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Familial Atrial Fibrillation Heart Disease
Hepatic Encephalopathy Hypertension, Essential
Hypoglycemia Hypothyroidism
Iron Deficiency Anemia Ischemic Heart Disease
Kidney Disease Parkinson Disease, Late-Onset
Peripheral Vascular Disease Protein-Energy Malnutrition
Respiratory Failure Schizophreniform Disorder
Status Epilepticus Swallowing Disorders
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Encephalopathy:



Diseases related to Encephalopathy

Symptoms & Phenotypes for Encephalopathy

UMLS symptoms related to Encephalopathy:


pseudobulbar signs, seizures, headache, catatonic reaction, sleeplessness, vertigo/dizziness, akathisia, hyperexplexia, opisthotonus, cogwheel rigidity, chronic pain, agitation, vertigo, tremor, torticollis, syncope, sciatica, pain, nervousness, myoclonus, hemiplegia, dystonia, dizziness, cerebellar ataxia, back pain, athetosis, ataxia

MGI Mouse Phenotypes related to Encephalopathy:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.32 CDKL5 DNM1L ETHE1 GNAO1 MECP2 PRNP

Drugs & Therapeutics for Encephalopathy

Drugs for Encephalopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1257)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
2
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 9005-49-6 46507594 772
3
Norepinephrine Approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-41-2 439260
4
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
5
Mannitol Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 69-65-8 6251 453
6
Vigabatrin Approved Phase 4,Phase 2,Not Applicable 68506-86-5, 60643-86-9 5665
7
Tiagabine Approved, Investigational Phase 4 115103-54-3 60648
8
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2 60142-96-3 3446
9
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 84057-84-1 3878
10
Phenytoin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 57-41-0 1775
11
Carbamazepine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 298-46-4 2554
12
Baclofen Approved Phase 4,Phase 2 1134-47-0 2284
13
Levodopa Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-92-7 6047
14
Nicotine Approved Phase 4,Not Applicable 54-11-5 89594 942
15
Glyburide Approved Phase 4,Phase 3,Phase 2,Phase 1 10238-21-8 3488
16
Probucol Approved, Investigational Phase 4,Phase 1,Phase 2 23288-49-5 4912
17
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-66-6 32051 23994
18
Testosterone Approved, Investigational Phase 4,Phase 2,Not Applicable 58-22-0 6013
19
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 50-78-2 2244
20
Verapamil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-53-9 2520
21
Methotrexate Approved Phase 4,Phase 3,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
22
Curcumin Approved, Investigational Phase 4,Phase 2,Phase 1 458-37-7 969516
23
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-43-4 5816
24
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
25
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59467-70-8 4192
26
Phenobarbital Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-06-6 4763
27
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
28
Morphine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 57-27-2 5288826
29
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 103-90-2 1983
30
Ibuprofen Approved Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 15687-27-1 3672
31
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 657-24-9 4091 14219
32
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 99-66-1 3121
33
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
34
Valsartan Approved, Investigational Phase 4,Not Applicable 137862-53-4 60846
35
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 2 58-93-5 3639
36
Atenolol Approved Phase 4,Phase 3 29122-68-7 2249
37
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 120202-66-6, 113665-84-2 60606
38
Nitroglycerin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 55-63-0 4510
39
Warfarin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81-81-2 54678486 6691
40
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 120014-06-4 3152
41
Galantamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 357-70-0 9651
42
Rivastigmine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 123441-03-2 77991
43
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-84-3 187
44
Huperzine A Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 102518-79-6
45
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 19982-08-2 4054
46 Piracetam Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7491-74-9
47
Rasagiline Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 136236-51-6 3052776
48
Metoclopramide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 364-62-5 4168
49
Cilostazol Approved, Investigational Phase 4,Phase 3,Early Phase 1,Not Applicable 73963-72-1 2754
50
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-45-6, 75614-87-8 774

Interventional clinical trials:

(show top 50) (show all 10228)

# Name Status NCT ID Phase Drugs
1 Metformin Experience on Minimal Hepatic Encephalopathy Unknown status NCT02470546 Phase 4 Metformin;Placebo
2 Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis Unknown status NCT01175538 Phase 4 Lactulose;Lactulose
3 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
4 Efficacy of Combined Oral L-Ornithine-L-Aspartate and Lactulose in Patients With Hepatic Encephalopathy Unknown status NCT00740142 Phase 4 L-ornithine-L-aspartate and lactulose;placebo and lactulose
5 Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy Unknown status NCT00896831 Phase 4 L-ornithine-L-aspartate;placebo
6 Trial Comparing Sedation for Endoscopy With Propofol Versus Midazolam in Cirrhotics Unknown status NCT01356121 Phase 4 Propofol;Midazolam
7 Rifaximin Versus Lactulose in Renal Failure Unknown status NCT00748904 Phase 4 Rifaximin;Lactulose
8 Magnesium in Liver Cirrhosis Unknown status NCT01894867 Phase 4
9 Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects Unknown status NCT01370486 Phase 4 melatonin;placebo
10 Efficacy of Yinzhihuang Oral Liquid on Indirect Bilirubin of Neonates With Glucose-6-phosphate Dehydrogenase Deficiency Unknown status NCT02594904 Phase 4 Yinzhihuang Oral Liquid
11 Use of a New Phototherapy Device (BBloo®) for the Treatment of Hyperbilirubinemia in the Newborn Infant Unknown status NCT02156050 Phase 4
12 Delayed Vasospasm After Aneurysm With the Standardization Treatment of Traditional Chinese Medicine Unknown status NCT01840761 Phase 4 herbal drug;placebo
13 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
14 Magnetic Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia Unknown status NCT00186771 Phase 4
15 Immunotherapy in Intractable Cryptogenic Epilepsy Patients With Autoimmune Antibody Unknown status NCT02695797 Phase 4 Prednisolone
16 NIMIP: Non Invasive Measurement of the Intracranial Pressure Unknown status NCT01685450 Phase 4
17 The Impact of Reducing Overtreatment on Quality of Life in Children With Refractory Epilepsy Unknown status NCT00647322 Phase 4
18 Hormone Profiles in Adults With Newly Diagnosed Epilepsy Unknown status NCT00137709 Phase 4 Sodium valproate;Lamotrigine
19 Study to Improve the Treatment of Epilepsy (SITE) Unknown status NCT00133081 Phase 4 All registered antiepileptic drugs
20 Compare Tolerability of an Overnight Switch to Gradual Switch Between Two Different Forms of Depakote Unknown status NCT00312676 Phase 4
21 Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes? Unknown status NCT00752934 Phase 4 oral baclofen + placebo;placebo + oral baclofen
22 A Clinical Trial of the Effect of Midazolam on the Cerebral Metabolism and Inflammatory Response in Patients With Moderate and Severe Traumatic Brain Injury Unknown status NCT02071407 Phase 4 Midazolam;Placebo
23 A Comparison of Propofol Versus Midazolam to Sedate Critically Brain Injury; Measurement of Cytokine Response and Assessment of Function Unknown status NCT01712477 Phase 4 Intravenous sedation using propofol;Intravenous sedation with midazolam
24 Growth Hormone and Brain Functioning After Traumatic Brain Injury Unknown status NCT01699308 Phase 4 Genotropin (somatropin)
25 The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery Unknown status NCT01606111 Phase 4 Cerebrolysin;0.9% NaCl, saline
26 Effect of Rozerem on Sleep Among People With Traumatic Brain Injury Unknown status NCT01207050 Phase 4 Ramelteon
27 The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients Unknown status NCT02532023 Phase 4
28 Occipital Transcutaneous Stimulation in Chronic Migraine Unknown status NCT02307071 Phase 4
29 Preventive Treatment of Episodic and Chronic Migraine Unknown status NCT01319825 Phase 4 milnacipran
30 A Randomized Trial of Valproate Versus Ketorolac Versus Metoclopramide for Acute Migraine Unknown status NCT01267864 Phase 4 Metoclorpamide;Ketorolac;Valproate
31 American Migraine Prevention Study Unknown status NCT00363506 Phase 4
32 CPAP for Infantile Pompe Disease Unknown status NCT02405624 Phase 4
33 Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease Unknown status NCT00487630 Phase 4 recombinant alpha-galactosidase A
34 The Effect of Dexmedetomidine to Cognition of Geriatrics in Prolonged Surgery Unknown status NCT02123355 Phase 4 Induction of anesthesia;Sevoflurane, remifentanil ,vecuronium;Dexmedetomidine;Placebo
35 Effectiveness and Safety of Yiqitongluo Granule for Stroke Unknown status NCT02604654 Phase 4 Yiqitongluo granule
36 4-point vs 4-roll Canne as Walking Aids After Stroke Unknown status NCT02279069 Phase 4
37 A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke Unknown status NCT02152280 Phase 4 Danhong Injection;Normal Saline
38 FINGER Robot Therapy Study Unknown status NCT02048826 Phase 4
39 Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients Unknown status NCT01819441 Phase 4 Azelnidipine;Perindopril;hydrochlorothiazide
40 Creative Therapy to Affect Stroke Outcomes Unknown status NCT01455155 Phase 4
41 Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke Patients Unknown status NCT00967408 Phase 4 Escitalopram;Placebo
42 Functional Electrical Stimulation (FES) Assisted Walking: Enhancement of Walking Function After Stroke Unknown status NCT00552916 Phase 4
43 Early Warning and Optimization Strategy in Carotid Endarterectomy Unknown status NCT01210937 Phase 4
44 Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia Unknown status NCT01012830 Phase 4 Huperzine A
45 Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) Unknown status NCT00108706 Phase 4 Candesartan
46 Consequence of Dexmedetomidine on Emergence Deliruim After Sevoflurane Anesthesia in Children With Cerebral Palsy Unknown status NCT02244515 Phase 4 dexmedetomidine
47 Evaluation of the Efficacy and Safety of Levothyroxine in Brain Death Organ Donors: a Randomized Controled Trial Unknown status NCT02211053 Phase 4 Levothyroxine;placebo
48 Intensive Versus Nonintensive Insulin Therapy for Hyperglycemia After Traumatic Brain Injury Unknown status NCT02161055 Phase 4 Insulin
49 Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Unknown status NCT01954810 Phase 4
50 Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease Unknown status NCT01849042 Phase 4 Ebixa;donepezil

Search NIH Clinical Center for Encephalopathy

Genetic Tests for Encephalopathy

Genetic tests related to Encephalopathy:

# Genetic test Affiliating Genes
1 Encephalopathy 28

Anatomical Context for Encephalopathy

MalaCards organs/tissues related to Encephalopathy:

38
Liver, Brain, Testes, Thyroid, Eye, Spleen, Heart

Publications for Encephalopathy

Articles related to Encephalopathy:

(show top 50) (show all 3792)
# Title Authors Year
1
Prediction of Hepatic Encephalopathy: Why disregard well known risk factors? ( 29377250 )
2018
2
Clinical Findings and Neurologic Outcome in Neonatal Encephalopathy With White Matter Injury Accompanied by Rotavirus. ( 29433417 )
2018
3
Improving Quality of Care for People with Hepatic Encephalopathy. ( 29411992 )
2018
4
Steroid pulse therapy in patients with encephalopathy associated with severe fever with thrombocytopenia syndrome. ( 29428565 )
2018
5
Deep brain stimulation in cerebral palsy: Time for dynamism in a static encephalopathy. ( 29447767 )
2018
6
Baicalin reverses the impairment of synaptogenesis induced by dopamine burden via the stimulation of GABA<sub>A</sub>R-TrkB interaction in minimal hepatic encephalopathy. ( 29404643 )
2018
7
Association of hemolysis, elevated liver enzymes, low platelets syndrome with posterior reversible encephalopathy and intracranial hypotension. ( 29322989 )
2018
8
Antepartum risk factors for moderate to severe neonatal hypoxic ischemic encephalopathy: a Swedish national cohort study. ( 29450878 )
2018
9
Disrupted Brain Intrinsic Networks and Executive Dysfunction in Cirrhotic Patients without Overt Hepatic Encephalopathy. ( 29422882 )
2018
10
Posterior Reversible Encephalopathy Syndrome Secondary to Acute PostStreptococcal Glomerulonephritis in a 12-year-old Girl. ( 29290203 )
2018
11
Effect of probiotic treatment on cirrhotic patients with minimal hepatic encephalopathy: A meta-analysis. ( 29428113 )
2018
12
An adult case with shigellosis-associated encephalopathy. ( 29351935 )
2018
13
EDITORIAL that refers to article 'Treating hepatic encephalopathy in cirrhotic patients admitted to ICU with sodium phenylbutyrate: a preliminary study'. ( 29430750 )
2018
14
Hypoxic-Ischemic Encephalopathy and Other Neonatal Encephalopathies. ( 29432237 )
2018
15
Teaching NeuroImages: Acute necrotizing encephalopathy of childhood: Neuroimaging findings. ( 29311376 )
2018
16
Benefits of starting hypothermia treatment within 6A h vs. 6-12A h in newborns with moderate neonatal hypoxic-ischemic encephalopathy. ( 29433475 )
2018
17
Preeclampsia: Association With Posterior Reversible Encephalopathy Syndrome and Stroke. ( 29438078 )
2018
18
Is Lactulose Plus Rifaximin Better than Lactulose Alone in the Management of Hepatic Encephalopathy? ( 29394969 )
2018
19
Wernicke Encephalopathy Following Laparoscopic Sleeve Gastrectomy-a Call to Evaluate Thiamine Deficiencies After Restrictive Bariatric Procedures. ( 29307105 )
2018
20
Effect of Post-Traumatic Stress Disorder on Cognitive Function and Covert Hepatic Encephalopathy Diagnosis in Cirrhotic Veterans. ( 29313245 )
2018
21
Effect of sirolimus on liver cirrhosis and hepatic encephalopathy of common bile duct-ligated rats. ( 29444470 )
2018
22
Hepatic encephalopathy: causes and health-related burden. ( 29411993 )
2018
23
Convergence Spasm in Wernicke Encephalopathy. ( 29276567 )
2018
24
The ketogenic diet is effective for refractory epilepsy associated with acquired structural epileptic encephalopathy. ( 29451698 )
2018
25
Diagnosis and management of hepatic encephalopathy. ( 29411990 )
2018
26
Multimodal MR imaging in hepatic encephalopathy: state of the art. ( 29374342 )
2018
27
Effects of Alcohol on the Brain in Cirrhosis: Beyond Hepatic Encephalopathy. ( 29417604 )
2018
28
Osmotic Shifts, Cerebral Edema, and Neurologic Deterioration in Severe Hepatic Encephalopathy. ( 29341965 )
2018
29
Re: Prediction of Hepatic Encephalopathy: why disregard well known risk factors? ( 29365345 )
2018
30
Hashimoto's encephalopathy presenting as pseudobulbar palsy. ( 29368307 )
2018
31
Human T-cell lymphotropic virus (HTLV)-associated encephalopathy: an under-recognised cause of acute encephalitis? Case series and literature review. ( 29423617 )
2018
32
Stroop Test Validation to Screen for Minimal Hepatic Encephalopathy in Pediatric Extrahepatic Portal Venous Obstruction. ( 29373442 )
2018
33
Impact of intestinal mannitol on hyperammonemia, oxidative stress and severity of hepatic encephalopathy in the ED. ( 29352675 )
2018
34
Encephalopathy after chocolate consumption. ( 29438643 )
2018
35
Fulminant encephalopathy with unusual brain imaging in disulfiram toxicity. ( 29440564 )
2018
36
Covert hepatic encephalopathy leads to distinct alterations in the emotional state, independently of MELD-Score. ( 29341039 )
2018
37
Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients. ( 29383024 )
2018
38
Fatal Necrotizing Encephalopathy after Treatment with Nivolumab for Squamous Non-Small Cell Lung Cancer: Case Report and Review of the Literature. ( 29441072 )
2018
39
Posterior reversible encephalopathy syndrome secondary to asymptomatic poststreptococcal glomerulonephritis in a child with sickle cell anemia: a case report. ( 29386039 )
2018
40
Focal segmental glomerulosclerosis in children complicated by posterior reversible encephalopathy syndrome. ( 29310486 )
2018
41
A patient with early myoclonic encephalopathy (EME) with a de novo KCNQ2 mutation. ( 28687180 )
2017
42
Mutations in TRAPPC12 Manifest in Progressive Childhood Encephalopathy and Golgi Dysfunction. ( 28777934 )
2017
43
Sea food consumption for improving cardiac and cerebral manifestations of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes. ( 28936463 )
2017
44
Routine fruit washing to prevent acute toxic encephalopathy - Authors' reply. ( 28807179 )
2017
45
Early hypoperfusion on arterial spin labeling may be a diagnostic marker for acute encephalopathy with biphasic seizures and late reduced diffusion. ( 28477981 )
2017
46
Compound heterozygous mutations in the gene PIGP are associated with early infantile epileptic encephalopathy. ( 28334793 )
2017
47
Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy. ( 28799305 )
2017
48
Performance characterization of a novel electronic number connection test to detect minimal hepatic encephalopathy in cirrhotic patients. ( 28092641 )
2017
49
Hypothermia Presenting in Wernicke Encephalopathy: A Case Report. ( 28289649 )
2017
50
Wernicke Encephalopathy ( 29261914 )
2017